NASDAQ:MRVI Maravai LifeSciences Q3 2025 Earnings Report $3.54 +0.03 (+0.71%) As of 10:35 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Maravai LifeSciences EPS ResultsActual EPSN/AConsensus EPS -$0.06Beat/MissN/AOne Year Ago EPSN/AMaravai LifeSciences Revenue ResultsActual RevenueN/AExpected Revenue$49.02 millionBeat/MissN/AYoY Revenue GrowthN/AMaravai LifeSciences Announcement DetailsQuarterQ3 2025Date11/6/2025TimeBefore Market OpensConference Call DateThursday, November 6, 2025Conference Call Time5:00PM ETConference Call ResourcesEarnings HistoryCompany Profile Maravai LifeSciences Earnings HeadlinesMaravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Consensus Rating of "Hold" by BrokeragesOctober 13, 2025 | americanbankingnews.comMARAVAI (MRVI) INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Investigation into Maravai LifeSciences Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmOctober 2, 2025 | globenewswire.comThis dark force is about to change everythingAn unstoppable force is reshaping America — one so powerful it’s already disrupting how we work, invest, and live. Porter Stansberry calls it The Final Displacement — a rare turning point that’s only happened four times in human history, each one redefining entire eras. His new documentary reveals why this shift could trigger both immense loss and unprecedented opportunity, and what you can do to prepare before it accelerates.October 21 at 2:00 AM | Porter & Company (Ad)MARAVAI INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Maravai LifeSciences Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmSeptember 9, 2025 | globenewswire.comRBC Capital Remains a Buy on Maravai Lifesciences Holdings (MRVI)September 7, 2025 | theglobeandmail.comMaravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | msn.comSee More Maravai LifeSciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Maravai LifeSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Maravai LifeSciences and other key companies, straight to your email. Email Address About Maravai LifeSciencesMaravai LifeSciences (NASDAQ:MRVI) (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry. Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows. The company’s TriLink® division supplies custom nucleic acids and enzymatic reagents for RNA and DNA synthesis, while its SeraCode™ and ExoScale™ offerings provide specialized tools for protein quantification and extracellular vesicle analysis. Maravai also offers contract development and manufacturing services to support scale-up and commercialization efforts for novel biologic candidates. Founded in 2015 and headquartered in San Diego, California, Maravai has grown through strategic acquisitions and organic innovation to serve clients in North America, Europe and Asia. The company partners with leading pharmaceutical and biotechnology organizations to advance vaccine programs, cell and gene therapies and precision diagnostics. Under the leadership of President and Chief Executive Officer Brent P. Saunders, Maravai continues to invest in research and development, expanding its global manufacturing footprint and strengthening its position in high-growth markets for advanced therapies.View Maravai LifeSciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done YetGoldman Sachs Earnings Tell: Markets Seem OkayWhy Congress Is Buying Intuitive Surgical Ahead of Earnings3 Reasons to Buy Sprouts Farmers Market Ahead of EarningsTesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 Earnings Upcoming Earnings O'Reilly Automotive (10/22/2025)Lam Research (10/22/2025)CME Group (10/22/2025)Tesla (10/22/2025)Barclays (10/22/2025)AT&T (10/22/2025)Kinder Morgan (10/22/2025)Boston Scientific (10/22/2025)Amphenol (10/22/2025)Vertiv (10/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
